Warren Neil Beverung, Jr

This inventor holds 6 USPTO granted patents. Top assignee: Bristol-Myers Company. Active years: 1976-1979.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Warren Neil Beverung, Jr. Retrieved from https://idiyas.com/inventor/warren-neil-beverung-jr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 100.0

Average Co-Inventor Count = 2.4

ph-index = 5

Forward Citations = 118(Granted Patents)

Location History:

Minoa, NY (US) (1976)
Fairfax, VA (US) (1979)

Company Filing History:

6 out of 637

Bristol-Myers Company

patents

Years Active: 1976-1979

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 4146718 - Alkyl 5,6-dichloro-3,4-dihydro-2(1H)-iminoquinazoline-3-acetate (1979-03-27),

2. 3988340 - 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and (1976-10-26),

3. 3983120 - Process for the preparation of optionally substituted (1976-09-28),

4. 3983119 - Process for the preparation of optionally substituted (1976-09-28),

5. 3974165 - Hypotensive agents (1976-08-10),

6. 3932407 - Optionally substituted (1976-01-13),

Title: The Innovations of Warren Neil Beverung, Jr.

Introduction

Warren Neil Beverung, Jr. is a notable inventor based in Minoa, NY (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as blood platelet antiaggregative agents. With a total of six patents to his name, Beverung's work has had a meaningful impact on medical science.

Latest Patents

Beverung's latest patents include the invention of Alkyl 5,6-dichloro-3,4-dihydro-2(1H)-iminoquinazoline-3-acetate, which is recognized as a known blood platelet antiaggregative agent. Another significant patent involves the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one, which is produced in high yield through an improved process that utilizes a novel intermediate. Additionally, he has developed compounds such as 6-alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones, which are useful as blood platelet anti-aggregative, antihypertensive, and bronchodilator agents in mammals, including humans.

Career Highlights

Beverung is currently associated with Bristol-Myers Company, where he continues to innovate and contribute to the pharmaceutical industry. His work has been instrumental in advancing the understanding and treatment of various medical conditions.

Collaborations

Throughout his career, Beverung has collaborated with notable colleagues such as Richard A Partyka and Thomas Andrew Jenks. These collaborations have further enriched his research and development efforts.

Conclusion

Warren Neil Beverung, Jr. stands out as a significant figure in the realm of pharmaceutical inventions. His innovative patents and contributions to medical science highlight his dedication to improving health outcomes.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]